<DOC>
	<DOCNO>NCT00997412</DOCNO>
	<brief_summary>This randomize , double-blind , double-dummy trial , objective compare efficacy safety Mycophenolic acid ( MA ) Azathioprine ( AZA ) , immunosuppressive drug , myasthenia gravis patient . This prospective study enroll 40 myasthenia gravis ( MG ) patient poor control prior steroid therapy . All subject randomly assign MA group AZA group receive routine pyridostigmine prednisolone combination MA AZA .</brief_summary>
	<brief_title>Trial Mycophenolic Acid Versus Azathioprine Treatment Corticosteroid-refractory Myasthenia Gravis</brief_title>
	<detailed_description>This double-dummy study keep blinded quality . - MA group : 1 tablet AZA placebo 4 table MA ( 180 mg/tab,720 mg/day ) twice daily . - AZA group : 1 tablet AZA ( 50mg/tab ) 4 table MA placebo twice daily . - When patient achieve minimal manifestation ( MM , i.e . complete remission ) , lead normal daily routine , dose pyridostigmine reduce 240 mg/day ( 4 tablet ) less . The dose steroid step 10 mg qod ( every day ) every 2 week dose achieves 40 mg qod . After , dose step 5 mg qod every month . - When disease progress long maintain minimal manifestation , dose steroid step 10 mg qod every 2 week achieve clinical stable remission . The taper rule steroid could start 1 month stabilization . - Every patient treat 1 year . If patient could achieve MM within 1 year , blind individual patient open patient cross another medical treatment . The efficacy safety second medication observe openly end study . - When muscle weakness worsens establish study schedule , plasmapheresis could conduct improve condition rapidly .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Male female age 2070 ( include 20 70 year old ) . Osserman II III Myasthenia Gravis . Positive serum antiacetylcholine receptor antibody . Poor control disease daily dose prednisone â‰¥ 30 mg 0.5 mg/kg 3 month enrollment . Without immunosuppressive therapy steroid . Ocular MG minimal clinical syndrome would require therapy steroid . Negative serum antiacetylcholine receptor antibody . Use immunosuppressant steroid precede year . Previous use investigational medication within 3 month current participate clinical study . Poor renal function : serum creatinine &gt; 3.0 mg/dl estimate creatinine clearance &lt; 30 ml/min Females pregnancy breastfeeding . Recent history , within 5 year , malignancy Unwilling unable participate necessary continuous visit examination .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>